文献速递肿瘤 PET/CT

基于交叉组合方法构建最优PET影像组学特征预测弥漫大B细胞淋巴瘤患者生存

Optimal PET-based radiomic signature construction based on the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-02-11

该研究纳入两个医疗中心2011至2019年的383例弥漫大B细胞淋巴瘤患者,采用交叉组合方法从三类PET影像组学特征中生成49个特征选择-分类候选模型并构建影像组学特征,结合代谢指标和临床危险因素建立生存预测模型。联合模型在无进展生存和总生存的区分度上均优于临床模型、PET模型及NCCN-IPI,外部验证C指数分别为0.758和0.794。

要点

  • 由12个和31个影像组学特征构建的R-signature分别与PFS和OS显著相关(P<0.05)。
  • 联合模型(R-signature+代谢指标+临床因素)在训练集PFS和OS的C指数分别为0.801和0.807。
  • 外部验证中联合模型PFS和OS的C指数分别为0.758和0.794,校准曲线一致性良好。

核心结论

  • R-signature可作为弥漫大B细胞淋巴瘤的生存预测指标,与临床因素结合可能有助于准确的风险分层。

研究设计与样本

  • 回顾性纳入两个医疗中心2011至2019年的383例弥漫大B细胞淋巴瘤患者,分为训练队列和外部验证队列。
  • 在训练队列中对三类PET影像组学特征应用交叉组合方法,基于7种不同机器学习模型生成49个特征选择-分类候选。
  • 根据无进展生存和总生存选择最优候选构建R-signature,采用Cox回归开发生存预测模型并进行外部验证。

主要发现

  • 由12个影像组学特征确定的R-signature与PFS显著相关,由31个特征确定的R-signature与OS显著相关(P<0.05)。
  • 联合模型在PFS的C指数为0.801,优于临床模型0.732、PET模型0.785和NCCN-IPI 0.720。
  • 联合模型在OS的C指数为0.807,优于临床模型0.740、PET模型0.773和NCCN-IPI 0.726。
  • 外部验证中,联合模型PFS的C指数为0.758,优于临床模型0.621、PET模型0.732和NCCN-IPI 0.673。
  • 外部验证中,联合模型OS的C指数为0.794,优于临床模型0.696、PET模型0.781和NCCN-IPI 0.708。

关键数值与推荐

  • R-signature分别由12个(PFS)和31个(OS)影像组学特征构成,均与相应终点显著相关(P<0.05)。
  • 训练集联合模型PFS的C指数为0.801,外部验证为0.758。
  • 训练集联合模型OS的C指数为0.807,外部验证为0.794。
  • 校准曲线显示良好一致性,决策曲线分析支持联合模型的临床效用。

临床怎么用

  • 原文结论认为R-signature可作为DLBCL的生存预测指标,与临床因素结合可能有助于准确的风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop and externally validate models incorporating a PET radiomics signature (R-signature) obtained by the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma (DLBCL). METHODS: A total of 383 patients with DLBCL from two medical centres between 2011 and 2019 were included. The cross-combination method was used on three types of PET radiomics features from the training cohort to generate 49 feature selection-classification candidates based on 7 different machine learning models. The R-signature was then built by selecting the optimal candidates based on their progression-free survival (PFS) and overall survival (OS). Cox regression analysis was used to develop the survival prediction models. The calibration, discrimination, and clinical utility of the models were assessed and externally validated. RESULTS: The R-signatures determined by 12 and 31 radiomics features were significantly associated with PFS and OS, respectively (P<0.05). The combined models that incorporated R-signatures, metabolic metrics, and clinical risk factors exhibited significant prognostic superiority over the clinical models, PET-based models, and the National Comprehensive Cancer Network International Prognostic Index in terms of both PFS (C-index: 0.801 vs. 0.732 vs. 0.785 vs. 0.720, respectively) and OS (C-index: 0.807 vs. 0.740 vs. 0.773 vs. 0.726, respectively). For external validation, the C-indices were 0.758 vs. 0.621 vs. 0.732 vs. 0.673 and 0.794 vs. 0.696 vs. 0.781 vs. 0.708 in the PFS and OS analyses, respectively. The calibration curves showed good consistency, and the decision curve analysis supported the clinical utility of the combined model. CONCLUSION: The R-signature could be used as a survival predictor for DLBCL, and its combination with clinical factors may allow for accurate risk stratification.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jiang C, Li A, Teng Y, et al. Optimal PET-based radiomic signature construction based on the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022. PMID: 35146578. doi:10.1007/s00259-022-05717-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。